THE COST-EFFECTIVENESS OF KETOCONAZOLE VERSUS METYRAPONE FOR THE TREATMENT OF CUSHING’S SYNDROME IN A SWEDISH SETTING

Author(s)

Björstad Å¹, Schmid R², Roser B²
¹Nordic Health Economics, Göteborg, Sweden, ²HRA Pharma, Paris, France

Presentation Documents

PDB45--strong-u-bjorstad-a-u-sup-1-sup-strong-schmid-r-sup-2-sup-roser-b-sup-2-sup-br-sup-1-sup-nordic-health-economics-goteborg-sweden-sup-2-sup-hra-pharma-paris-france

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PDB45

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Diabetes/Endocrine/Metabolic Disorders

Explore Related HEOR by Topic

Economic Evaluation

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now